Eli Lilly (LLY) said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Jaypirca to treat certain adult patients with relapsed or refractory chronic lymphocytic leukemia.

The recommendation is based on data from a phase 3 trial, in which the therapy met its primary endpoint of progression-free survival, Lilly said.

The European Commission will make a final decision in next one or two months, the company said.